Table 3.
Clinical and pathological characteristics of the 136 patients treated with neoadjuvant chemotherapy for esophageal and gastro-esophageal adenocarcinoma, classified as responders Tumour regression grade 1-2 or non-reponders tumour regression grade 3-5 n (%)
| TRG 1-2 36 (26.5) | TRG 3-5 100 (73.5) | P value | ||
| Preoperative status | ||||
| Age (range) yr1 | 65.27 (26.99-76.04) | 63.51 (32.77-81.28) | 0.410 | |
| Sex ratio (M:F)1 | 32 (88.9):4 (11.1) | 86 (86):14 (14) | 0.662 | |
| cT stage | 1 | 0 (0) | 0 (0) | 0.396 |
| 2 | 2 (5.6) | 14 (14) | ||
| 3 | 33 (91.7) | 81 (81) | ||
| 4 | 1 (2.8) | 5 (5) | ||
| cN stage | 0 | 5 (13.9) | 14 (14) | 0.987 |
| 1 | 31 (86.1) | 86 (86) | ||
| cM stage | 0 | 35 (97.1) | 99 (99) | 0.456 |
| 1 | 1 (2.8) | 1 (1) | ||
| Performance status | 0 | 12 (33.3) | 23 (23) | 0.225 |
| 1 | 23 (63.9) | 73 (73) | ||
| 2 | 1 (2.8) | 4 (4.0) | ||
| ASA | 1 | 2 (5.6) | 9 (9.1) | 0.408 |
| 2 | 32 (88.9) | 74 (74.7) | ||
| 3 | 2 (5.6) | 16 (16.2) | ||
| O-POSSUM | 15 (12-23) | 16 (12-26) | 0.476 | |
| Tumour site | Middle 1/3 | 1 (2.8) | 0 (0) | 0.738 |
| Lower 1/3 | 15 (41.7) | 42 (42) | ||
| GEJ-S1 | 7 (19.4) | 16 (16) | ||
| GEJ-S2 | 9 (25) | 25 (25) | ||
| GEJ-S3 | 4 (11.1) | 16 (16) | ||
| Operative outcomes | ||||
| Length of operation (min)1 | 262 (163-427) | 260 (120-471) | 0.513 | |
| Blood loss (mL)1 | 300 (0-3000) | 325 (0-1700) | 0.673 | |
| Clavien Dindo Max | 0 | 14 (38.9) | 39 (39.4) | 0.531 |
| 1 | 2 (5.6) | 6 (6.1) | ||
| 2 | 14 (38.9) | 26 (26.3) | ||
| 3 | 4 (11.1) | 13 (13.1) | ||
| 4 | 2 (5.6) | 15 (15.2) | ||
| 5 | 0 (0) | 0 (0) | ||
| Anastomotic leaks | 1 (2.8) | 8 (8.1) | 0.276 | |
| Pathological outcomes | ||||
| yPT | 0 | 8 (22.2) | 0 (0) | < 0.0001 |
| 1 | 11 (30.6) | 12 (12) | ||
| 2 | 9 (25) | 25 (25) | ||
| 3 | 8 (22.2) | 58 (58) | ||
| 4 | 0 (0) | 5 (5) | ||
| yPN | 0 | 34 (94.4) | 39 (39) | < 0.0001 |
| 1 | 0 (0) | 21 (21) | ||
| 2 | 2 (5.6) | 23 (23) | ||
| 3 | 0 (0) | 17 (17) | ||
| yPM | 0 | 36 (100) | 100 (100) | 0.579 |
| Nodal downstaged (cN1 to ypN0) | 30 (83.3) | 30 (30) | < 0.0001 | |
| Positive nodes1 | 0 (0-5) | 1 (0-24) | < 0.0001 | |
| Nodal yield1 | 18 (4-25) | 18 (3-53) | 0.984 | |
| Resection clearance | R0 | 35 (97.2) | 75 (75) | 0.004 |
| Vascular invasion | 4 (11.1) | 37 (37) | 0.004 | |
| Lymphatic invasion | 4 (11.1) | 18 (18) | 0.338 | |
| Perineural invasion | 2 (5.6) | 18 (18) | 0.072 | |
| Maximum tumour diameter1 | (mm) | 15 (0-110) | 30 (0-155) | < 0.0001 |
| Morphology | Ulcer | 30 (93.8) | 66 (68) | 0.003 |
| Polypoid | 2 (6.3) | 21 (21.6) | ||
| Fungating | 0 (0) | 3 (3.1) | ||
| Diffuse infiltrating | 0 (0) | 7 (7.2) | ||
| Grade | G1 | 8 (22.2) | 8 (8) | 0.104 |
| G2 | 9 (25) | 28 (28) | ||
| G3 | 19 (52.8) | 63 (63) | ||
| G4 | 0 (0) | 1 (1) | ||
| Sites of recurrence | Local | 0 (0) | 8 (8.1) | 0.080 |
| Nodal | 1 (2.8) | 13 (13.1) | 0.082 | |
| Distant | 2 (5.6) | 42 (42.4) | < 0.0001 |
Values in parentheses are percentages unless indicated.
1
Values in parentheses are range. TRG: Tumour Regression Grade; ASA:American Society of Anesthesiologists classification; O-POSSUM: Oesophagogastric surgery-physiological and operative severity score for the enumeration of mortality and morbidity; GEJ-S1-3: Gastro-esophageal junction-Siewert type 1-3.